In EDS ansehen

Landiolol is effective and safe in paediatric supraventricular tachycardia: evidence from a European prospective multicentre open-label phase III study (LANDI-PED)

Gespeichert in:
Bibliographische Detailangaben
Titel: Landiolol is effective and safe in paediatric supraventricular tachycardia: evidence from a European prospective multicentre open-label phase III study (LANDI-PED)
Autoren: Ina Michel-Behnke, Matthias Müller, Brigitte Stiller, Thomas Kriebel, Majed Kanaan, László Környei, Matthias Mai, Roman Gebauer, Jens Meier, Ferran Roses-Noguer, Martin Unger, Stefanie Schlager, Charu Charu, Christoph Klade, Kurt Krejcy, Jakob Ackerl, Günther Krumpl
Weitere Verfasser: Institut Català de la Salut, [Michel-Behnke I] Department of Paediatrics and Adolescent Medicine, Division of Paediatric Cardiology, Medical University of Vienna, General Hospital Vienna, Vienna, Austria. [Müller M] Department of Anaesthesiology and Intensive Care Medicine, Paediatric Heart Centre Giessen, University Hospital Giessen and Marburg GmbH, Giessen, Germany. [Stiller B] Department of Congenital Heart Disease and Paediatric Cardiology, Faculty of Medicine, Heart Centre Freiburg University, University of Freiburg, Freiburg, Germany. [Kriebel T] Department of Paediatrics and Paediatric Cardiology, Westpfalz Hospital, Kaiserslautern, Germany. [Kanaan M] Department of Paediatric Cardiology, Children’s Heart Centre Aachen, University Hospital RWTH Aachen, Aachen, Germany. [Környei L] Gottsegen National Cardiovascular Centre, Paediatric Heart Centre, Budapest, Hungary. [Roses-Noguer F] Servei de Cardiologia Pediàtrica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Honorary Paediatric EP Consultant, Royal Brompton and Harefield Hospital, London, UK and European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart (ERN GUARD-Heart), Vall d'Hebron Barcelona Hospital Campus
Quelle: Europace
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Verlagsinformationen: Oxford University Press (OUP), 2025.
Publikationsjahr: 2025
Schlagwörter: Male, Time Factors, Adolescent, Other subheadings::Other subheadings::/therapeutic use, NAMED GROUPS::Persons::Age Groups::Child, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Morpholines, Taquicàrdia - Tractament, Adrenergic beta-Antagonists, Otros calificadores::Otros calificadores::/uso terapéutico, DENOMINACIONES DE GRUPOS::personas::Grupos de Edad::niño, DISEASES::Cardiovascular Diseases::Heart Diseases::Arrhythmias, Cardiac::Tachycardia::Tachycardia, Supraventricular, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::fármacos cardiovasculares::antiarrítmicos, Clinical Research, Heart Rate, Tachycardia, Supraventricular, Humans, Urea, Prospective Studies, Child, Infusions, Intravenous, Other subheadings::Other subheadings::Other subheadings::/drug therapy, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Cardiovascular Agents::Anti-Arrhythmia Agents, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, Antiarítmics cardíacs - Ús terapèutic, Infant, Newborn, Age Factors, Infant, ENFERMEDADES::enfermedades cardiovasculares::enfermedades cardíacas::arritmias cardíacas::taquicardia::taquicardia supraventricular, Europe, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento, Treatment Outcome, Child, Preschool, Avaluació de resultats (Assistència sanitària), Female, Infants, Anti-Arrhythmia Agents
Beschreibung: Aims Landiolol, an ultra-fast acting super-selective beta-blocker, was investigated for the first time in Europe in a prospective clinical study for the management of supraventricular tachycardia (SVT) among paediatric patients. Methods and results The LANDI-PED study was a prospective, multicentre, open-label, uncontrolled phase III study aiming to investigate the efficacy, safety, and pharmacokinetics (PK) of landiolol in paediatric patients. Sixty patients in surgical and non-surgical settings aged ≥1 day to Conclusion Landiolol is effective and safe in the treatment of SVTs in the paediatric population as demonstrated by reduction of HR and/or restoring NSR. Landiolol was well tolerated with no novel safety concerns reported. Clinical Trial Registration EU Clinical Trial Register; EudraCT Number: 2015-001129-17.
Publikationsart: Article
Other literature type
Dateibeschreibung: application/pdf; pdf
Sprache: English
ISSN: 1532-2092
1099-5129
DOI: 10.1093/europace/euaf025
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39947241
http://hdl.handle.net/11351/12910
Rights: CC BY
URL: http://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Dokumentencode: edsair.doi.dedup.....3a1ffcee8c59e90fa6e83b2e7fd4c71c
Datenbank: OpenAIRE
Beschreibung
Abstract:Aims Landiolol, an ultra-fast acting super-selective beta-blocker, was investigated for the first time in Europe in a prospective clinical study for the management of supraventricular tachycardia (SVT) among paediatric patients. Methods and results The LANDI-PED study was a prospective, multicentre, open-label, uncontrolled phase III study aiming to investigate the efficacy, safety, and pharmacokinetics (PK) of landiolol in paediatric patients. Sixty patients in surgical and non-surgical settings aged ≥1 day to Conclusion Landiolol is effective and safe in the treatment of SVTs in the paediatric population as demonstrated by reduction of HR and/or restoring NSR. Landiolol was well tolerated with no novel safety concerns reported. Clinical Trial Registration EU Clinical Trial Register; EudraCT Number: 2015-001129-17.
ISSN:15322092
10995129
DOI:10.1093/europace/euaf025